Bharat Biotech announced the successful recruitment of 23,000 volunteers and continued progress towards achieving the goal of 26,000 participants for phase 3 clinical trial of its coronavirus vaccine Covaxin across a couple of sites in India, news agency ANI quoted the pharma firm as saying on Saturday.
The announcement came hours after the subject expert committee of the Central Drugs Standard Keep watch over Organisation (CDSCO) advisable the vaccine for restricted emergency use.
Covaxin, the indigenous Covid-19 vaccine, is being developed by Hyderabad-based Bharat Biotech in organization with the Indian Council of Medical Research and National Institute of Virology. It is the second one vaccine in India that has moved closer to the last approval for emergency use against the lethal disease. Serum Institute of India’s Covishield was once provided the recommendation Friday and now both the vaccine candidates await the last approval from the Drug Controller General of India (DCGI).
Also Read| In a first, India successfully isolates new UK Covid-19 variant: ICMR
Bharat Biotech had applied for emergency-use authorisation first on December 7. The panel had then asked the firm to submit its safety and efficacy data from the ongoing phase 3 clinical trial for further consideration.
The third phase of Covaxin trial is still underway while the company has already published the findings of the first two rounds. It followed a double-bind, randomised, multi-centre phase two clinical trial which included children as mannered.
Also Read: Day 1 of dry run concludes as two Covid-19 vaccines await last nod
Though there is not any official word on the cost of the vaccine, Dr Krishna Ella, the MD of Bharat Biotech, had earlier said that it is going to be inexpensive. “Cheaper than a water bottle”, he had said in a convention, pointing to a water bottle. Since his remark, it has been estimated that it is going to come at a cost lower than Rs 100.[ad_2]